Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6874690 | 0.77 | — | — | |
| SCHEMBL26521598 | 0.76 | CCR1 (0.30) | — | |
| SCHEMBL21160316 | 0.76 | — | — | |
| SCHEMBL20604695 | 0.73 | — | — | |
| SCHEMBL29956350 | 0.73 | PLAU (0.32) | — | |
| SCHEMBL15979195 | 0.71 | — | — | |
| SCHEMBL22489731 | 0.71 | — | — | |
| SCHEMBL10176196 | 0.70 | — | — | |
| SCHEMBL15608951 | 0.70 | — | — | |
| SCHEMBL20518940 | 0.70 | AOC1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287062-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | KINESID THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| WO-2022236319-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236319-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4045025-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076945-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076945-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-28 | — | — | US | disclosed |
| EP-2595482-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018105-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | TXNRD2, TXNRD1, SDHB | CYP11B2 5/4885CYP3A4 706/4885CYP11B1 6/4885 |
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | HSD11B1, CYP11B2, HSD11B2 | CYP11B2 2/4885CYP3A4 88/4885CYP11B1 4/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | CYP11B2 701/4885CYP3A4 649/4885CYP11B1 433/4885 |
| US-20240287062-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | BRAF, NRAS, ABL1 | CYP11B2 3043/4885CYP3A4 3677/4885CYP11B1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.